Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Diageo's share price has dropped 15.3% in the year to date. Could it be about to become one of the FTSE 100's best recovery ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Live Updates Live Coverage Has Ended No News Is Good News 4:18 pm The trading day has ended, and the Federal Reserve meeting, ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Eli Lilly (LLY) shares rose on Wednesday as rival Novo Nordisk cut its full-year sales and profit guidance, reflecting ...

Investors have concluded that America Inc is reliving the covid shock on fast-forward. Within a month of Mr Trump’s surprise ...

Entering the first full trading hour of Wednesday's session, Madison Mills monitors several of the day's developing market ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...